Ruxolitinib
- Generic Name
- Ruxolitinib
- Brand Names
- Jakafi, Jakavi, Opzelura
- Drug Type
- Small Molecule
- Chemical Formula
- C17H18N6
- CAS Number
- 941678-49-5
- Unique Ingredient Identifier
- 82S8X8XX8H
- Background
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant act...
- Indication
Ruxolitinib is indicated for the treatment of the following conditions:
Topical ruxolitinib is indicated for:
- Associated Conditions
- Acute Graft-Versus-Host Disease (GVHD), Chronic Graft-Versus-Host Disease, Non-segmental Vitiligo, Post Polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis (Post-ET MF), Primary Myelofibrosis (PMF), High risk Myelofibrosis, Intermediate risk Myelofibrosis, Mild Atopic dermatitis, Moderate Atopic dermatitis, Refractory Polycythemia vera
- Associated Therapies
- -
RVU120 in Patients with Intermediate or High-risk, Primary or Secondary Myelofibrosis
- First Posted Date
- 2024-05-02
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Ryvu Therapeutics SA
- Target Recruit Count
- 230
- Registration Number
- NCT06397313
- Locations
- 🇮🇹
Policlinico Sant'Orsola-Malpighi, Bologna, Italy
🇮🇹Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia, Brescia, Italy
🇮🇹Azienda Ospedaliero Universitaria Policlinico "G. Rodolico - San Marco", Catania, Italy
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
- Conditions
- Interventions
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 120
- Registration Number
- NCT06388564
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸University of California-Los Angeles Medl Cntr-Oncology Center Bowyer Clinic, Los Angeles, California, United States
🇺🇸Mayo Clinic Hospital, Phoenix, Arizona, United States
Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD
- Conditions
- Interventions
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 118
- Registration Number
- NCT06364319
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT06345495
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Open Label Phase 2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
- Conditions
- Interventions
- First Posted Date
- 2024-03-25
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 33
- Registration Number
- NCT06327100
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation
- Conditions
- Interventions
- First Posted Date
- 2024-03-04
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 18
- Registration Number
- NCT06291987
- Locations
- 🇺🇸
University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States
JAK Inhibitor in Acquired Hemophagocytic synDrome in the Intensive Care Unit
- First Posted Date
- 2024-02-06
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 42
- Registration Number
- NCT06244862
Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD
- Conditions
- Interventions
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Stefanie Sarantopoulos, MD, PhD.
- Target Recruit Count
- 30
- Registration Number
- NCT06233110
- Locations
- 🇺🇸
Duke, Durham, North Carolina, United States
A Trial of Selinexor, Ruxolitinib and Methylprednisolone
- Conditions
- Interventions
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Oncotherapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT06225310
PTCy and and Ruxolitinib for GVHD Prophylaxis After HSCT With Thymoglobulin in Conditioning Regimen in Patients With Inborn Errors of Immunity
- Conditions
- Interventions
- First Posted Date
- 2024-01-10
- Last Posted Date
- 2024-01-10
- Target Recruit Count
- 100
- Registration Number
- NCT06199427
- Locations
- 🇷🇺
HSCT department, Moscow, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.